Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MULTIPLE SCLEROSIS

Combining biomarkers to profile multiple sclerosis patients

Nature Reviews Neurology volume 16, pages 463–464 (2020)Cite this article

Subjects

Combined assessment of latest-generation molecular and MRI biomarkers has provided insight into the dynamics of brain volume loss after immunoablative autologous haematopoietic stem cell transplantation in multiple sclerosis, shedding light on the transient neurotoxic effects of this procedure.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).

    Article  Google Scholar 

  2. Comabella, M. & Montalban, X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 13, 113–126 (2014).

    Article  Google Scholar 

  3. Lassmann, H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front. Immunol. 9, 3116 (2019).

    Article  Google Scholar 

  4. Comabella, M., Sastre-Garriga, J. & Montalban, X. Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr. Opin. Neurol. 29, 254–262 (2016).

    Article  CAS  Google Scholar 

  5. Thebault, S. et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann. Clin. Transl Neurol. https://doi.org/10.1002/acn3.51045 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).

    Article  CAS  Google Scholar 

  7. Hogel, H. et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult. Scler. 26, 210–219 (2020).

    Article  CAS  Google Scholar 

  8. Sastre-Garriga, J. et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat. Rev. Neurol. 16, 171–182 (2020).

    Article  Google Scholar 

  9. Chen, J. T. et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66, 1935–1937 (2006).

    Article  CAS  Google Scholar 

  10. Petzold, A. et al. Evidence for acute neurotoxicity after chemotherapy. Ann. Neurol. 68, 806–815 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

    Nicola De Stefano

  2. Tuscany Centre for Precision Medicine (CREMEP), Siena, Italy

    Nicola De Stefano

  3. Department of Health Sciences, University of Genova, Genova, Italy

    Maria Pia Sormani

  4. IRCCS Ospedale Policlinico San Martino, Genova, Italy

    Maria Pia Sormani

Authors
  1. Nicola De Stefano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Pia Sormani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Pia Sormani.

Ethics declarations

Competing interests

N.D.S. has received honoraria from Biogen-Idec, Celgene, Immunic, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva for consulting services, speaking and travel support. He serves on advisory boards for Biogen-Idec, Immunic, Merck Serono, Novartis, Roche and Sanofi-Genzyme. He has received research grant support from the Italian Multiple Sclerosis Society. M.P.S. has received consulting fees from Biogen, Celgene, GeNeuro, Immunic, Medday, Merck, Mylan, Novartis, Roche and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stefano, N.D., Sormani, M.P. Combining biomarkers to profile multiple sclerosis patients. Nat Rev Neurol 16, 463–464 (2020). https://doi.org/10.1038/s41582-020-0378-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-020-0378-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research